Related Experiment Videos
A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic
Alaa Alkhalaf1, Astrid Klooster, Willem van Oeveren
1Department of Internal Medicine, University Medical Center Groningen, Groningen, the Netherlands. a.alkhalaf@int.umcg.nl
Objective:
To investigate the effect of benfotiamine on urinary albumin excretion (UAE) and the tubular damage marker kidney injury molecule-1 (KIM-1) in patients with type 2 diabetes and nephropathy.
Research Design And Methods:
Patients with type 2 diabetes and UAE equivalent to 15-300 mg/24 h, despite ACE inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs), were randomly assigned to 12 weeks of benfotiamine (900 mg/day) (n = 39) or placebo (n = 43).
Results:
Compared with placebo, benfotiamine treatment resulted in significant improvement of thiamine status (P < 0.001). Benfotiamine treatment did not significantly decrease 24-h UAE or 24-h KIM-1 excretion.
Conclusions:
In patients with type 2 diabetes and nephropathy, high-dose benfotiamine treatment for 12 weeks in addition to ACE-Is or ARBs did not reduce UAE or KIM-1 excretion, despite improvement of thiamine status.
Related Concept Videos
Diabetic Nephropathy
Bioavailability Study Design: Healthy Subjects Versus Patients
Diabetic Retinopathy
Diabetic Neuropathy
Blinding
Clinical Trials: Overview